Nuvelo & Amgen 50/50 Partnership
Alfimeprase identified through research programs at Amgen
Partnered with Amgen in January 2002
50/50 cost/profit sharing
Amgen received warrants, no up front cash
Nuvelo pays for development until we match Amgen’s investment
- Approximately mid Phase III
Deal structure leverages respective strengths of each company
- Nuvelo leads clinical development activities
- Amgen leads manufacturing activities
- Both companies have worldwide commercialization rights
- Amgen has the option to lead commercialization